Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-19
1999-12-28
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514215, 514217, 514316, 514352, 540547, 540550, 540557, 540587, 540588, 546187, 546285, 5483044, 5483097, C07D23504, C07D23506, C07D21106, C07D21302
Patent
active
060082135
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to pharmaceutically active compounds which bind to integrins, such as the vitronectin receptor and fibrinogen receptor. Such compounds are useful for inhibiting platelet aggregation and osteoclast attachment to bone.
BACKGROUND OF THE INVENTION
Integrins are a family of heterodimeric proteins which generally mediate cell adhesion. Typical of such proteins are the vitronectin receptor (an .alpha..sub.V .beta..sub.3 heterodimer) and the fibrinogen receptor (an .alpha..sub.IIb .beta..sub.3 heterodimer). The natural ligands of these receptors (e.g., vitronectin and fibrinogen) have been found to share a common -Arg-Gly-Asp- amino acid sequence, which appears to be critical for binding. In fact, many of the integrin receptors appear to cross react with ligands which possess such an amino acid sequence. For instance, the .alpha..sub.IIb .beta..sub.3 receptor reacts with fibronectin and vitronectin, thrombospondin and von Willebrand factor, as well as fibrinogen. Functionally fibrinogen, a dimer having two binding sites for .alpha..sub.IIb .beta..sub.3, reacts with activated receptors found on the surface of platelets. The binding of .alpha..sub.IIb .beta..sub.3 receptors on adjacent platelets, by fibrinogen leads to crosslinking and is considered to be a major factor in platelet aggregation. Compounds which inhibit the binding of the .alpha..sub.IIb .beta..sub.3 receptor to fibrinogen have been shown to inhibit the platelet aggregation in vitro, and thrombus formation in vivo. See, for instance, EP-A 0 341 915.
The vitronectin receptor is found on a variety of cell types, such as on osteoclasts and the endothelial cells lining blood vessels. Recent studies have indicated that the attachment of osteoclasts to the bone matrix is mediated through these cell surface adhesion receptors. For instance, Davies, et al., J. Cell Biol., 1989, 109, 1817, disclose that the osteoclast functional antigen, which is implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. The vitronectin receptor is known to bind to bone matrix proteins, such as osteopontin, bone sialoprotein and thrombospondin, which contain the tri-peptide Arg-Gly-Asp (or RGD) motif. Thus, Horton, et al., Exp. Cell Res. 1991, 195, 368, disclose that RGD-containing peptides and an anti-vitronectin receptor antibody (23C6) inhibit dentine resorption and cell spreading by osteoclasts. Bertolini et al., J. Bone Min. Res., 6, Sup. 1, S146, 252 have shown that cylco-S,S-N.sup..alpha. -acetyl-cysteinyl-N.sup..alpha. -methyl-argininyl-glycyl-aspartyl-penicillamine amide inhibits osteoclast attachment to bone. In addition, Sato, et al., J. Cell Biol. 1990, 111, 1713 disclose that echistatin, a snake venom peptide which contains the RGD sequence, is a potent inhibitor of bone resorption in tissue culture, and inhibits attachment of osteoclasts to bone. Fisher, et al., Endocrinology 1993, 132, 1411, has further shown that echistatin inhibits bone resorption in vivo in the rat. EP 528 587 and 528 586 report substituted phenyl derivatives which inhibit osteoclast mediated bone resorption.
Bondinell, et aL, in WO 93/00095 (PCT/US92/05463) and WO 94/14776 (PCT/US93/12436) disclose that certain compounds which have a substituted 6-7 bicyclic ring system are useful for inhibiting the fibrinogen (.alpha..sub.IIb .beta..sub.3) receptor. Other 6-7 bicyclic ring systems which inhibit the fibrinogen receptor are disclosed by Blackburn et al. in WO 93/08174 (PCT/US92/08788). Blackburn et al., WO 95/04057 (PCT/US94/07989) also disclose compounds which have a five- or six-membered ring fused to such 6-7 bicyclic ring to form a tricyclic ring system, which are useful as antagonists of the fibrinogen receptor. Other compounds having 6-7 bicyclic ring systems that selectively inhibit the vitronectin receptor are disclosed in WO 96/00730 (PCT/US95/08306) and WO 96/00574 (PCT/US95/08146). It has now been discovered that certain new tricyclic ring systems are useful templates for preparing integr
REFERENCES:
patent: 3906040 (1975-09-01), Vincent et al.
patent: 3972936 (1976-08-01), Christy
patent: 5302602 (1994-04-01), Oshima et al.
patent: 5726192 (1998-03-01), Bondinell et al.
patent: 5756519 (1998-05-01), Bondinell et al.
Bondinell William E.
Miller William H.
Kinzig Charles M.
McCarthy Mary E.
Rao Deepak R.
Raymond Richard L.
SmithKline Beecham Corporation
LandOfFree
Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2382532